68Ga-CD73 PET/CT imaging for diagnosing malignant tumors
Official title: Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
Run by Peking Union Medical College Hospital · NCT06844110 · Data updated 2026-11-12
This uses a 68Ga-DOTA-dPNE PET/CT scan that targets CD73 to see if it can detect malignant tumors and help predict response to targeted therapies in adults with measurable solid tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dongcheng, Beijing Municipality) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | December 30, 2025 |
| Study ends | March 30, 2026 |
| Registry record updated | August 5, 2025 |
| Trial ID | NCT06844110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18 years) with at least one RECIST 1.1 measurable solid tumor, expected survival ≥12 weeks, who can undergo biopsy or surgery and lie flat for imaging.
✕Probably not a fit
Patients with severe liver or kidney dysfunction, pregnant or breastfeeding women, those unable to lie flat or with claustrophobia, or patients whose tumors do not express CD73 are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants with measurable solid tumors receive a 68Ga-DOTA-dPNE PET/CT scan to visualize tracer binding and estimate CD73 expression in lesions. Imaging findings will be compared with pathological samples when surgery or biopsy is available and correlated with clinical indicators to explore links with treatment response. Eligible participants are adults with at least one RECIST 1.1 measurable lesion, expected survival ≥12 weeks, able to undergo biopsy or surgery, and without recent chemotherapy or radiotherapy. The protocol seeks to determine whether this targeted PET probe can improve localization of CD73-expressing tumors and provide information useful for guiding targeted therapy.
Why it matters
Potential benefit: If successful, this imaging method could provide a noninvasive way to identify CD73-expressing tumors and help guide selection and prediction of response to targeted treatments.
How similar studies have gone: CD73-targeted PET imaging is relatively novel: preclinical studies support the approach and only limited early clinical imaging data exist, although other immune-targeted PET tracers have shown promise in early studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1: Age: ≥18 years, expected survival ≥12 weeks 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion 4: Obtain written informed consent and be able to follow up Exclusion Criteria: \- 1: Severe liver and kidney dysfunction. 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study. 3: Individuals unable to lie flat for thirty minutes. 4: Suffers from claustrophobia or other mental illnesses 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study 6: Refuses to join this clinical study
Where it's running
-
Pumch
Dongcheng, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Xianzhong Zhang, PhD — Peking Union Medical College Hospital
- Study coordinator: Chenhao Jia
- Email: jiachenhao24@163.com
- Phone: 18548703382
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining radiofrequency ablation with carrizumab for advanced liver cancer
This study tests if adding a heat treatment called radiofrequency ablation to a new drug, carrizumab, can help people with advanced liver cancer live longer without their cancer getting worse compared to just using carrizumab alone.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Glycogen Storage Disease and Brain Function in People Like You
This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.
-
FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy
This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.
-
Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer
This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.